Skip to main content

Table 1 Summary of MDA characteristics at both sites

From: Community participation during two mass anti-malarial administrations in Cambodia: lessons from a joint workshop

 

Battambang

Preah Vihear

Sites

Four villages (two intervention villages in 2015 and two intervention villages in 2016). Total population 2366

Eight intervention villages simultaneously

Total population 7583

Site selection

Selected based on P. falciparum prevalence survey results and village malaria worker treatment records

Selected based on P. falciparum prevalence survey results and presence of K13 mutated parasites

Anti-malarial

DHA–PPQ

DHA–PPQ

Preparation period

Long (8 weeks, plus 4 weeks in the study villages): discussions on strategy and safety delayed the protocol approval and in effect increased preparation time

Short (about 6 weeks)

Late approval of the protocol reduced the time available to plan the project, planned to be done in the dry season

Drug administration procedure

Central. DOT by local health centre nurses (central village location in 2015; at a central location or house-to-house in 2016)

House to house. DOT ensured by teams going from house to house

MDA schedule

Three doses over 3 days—at monthly intervals for 3 months. Post-MDA, weekly identification of newcomers, especially forest returnees. A single 3-day course of DHA–PPQ offered new arrivals 12 months following MDA

Three doses over 3 days—at monthly intervals for 3 months. Decision taken to halt after low participation, MDA stopped after round one

Timing of MDA

July to September (early rainy season) 2015 in the first two villages and 2016 in the remaining two villages

March–April 2015 (pre-rainy season)

Safety monitoring and follow-up

Direct solicitation of adverse events over 3 days of drug administration by local health centre nurses, and again on the 7th day by village volunteers to record and assist with any adverse events. 30 days of passive follow up

External medical teams (two MoH nurses/village—two MSF physician) present in villages during 3 days of DOT + 2 days later follow up adverse events. MSF nurses were also present 24 h per day in health facilities during intake 1-month post-MDA

Informed consent

Community meetings and census used to explain study to each household head. Individual written signed consent

Community meetings to explain MDA. Verbal consent from community leaders and household heads. Written consent from individual participants

Incentives

KHR 10000 (~ US$2.5) per round and participant for round 1 (none for rounds 2 and 3 in 2016)

None

Other benefits

Free health service for minor conditions during MDA, provided by local health centre staff and supervised by a study physician

Healthcare was provided by an MSF nurse and MD in health facilities (additional to usual local staff). Transport was provided to referral facilities. Other medical costs were reimbursed until 1 month after intake

  1. DHA–PPQ dihydroartemisinin–piperaquine, DOT directly observed treatment, MDA mass drug administration, MoH Ministry of Health, PCD passive case detection, MD medical doctor, MSF Medecins sans frontiers